{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:14:38Z","timestamp":1793103278365,"version":"4.5.0"},"reference-count":70,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Fabry disease (FD) is an X-linked lysosomal storage disorder caused by mutations in the galactosidase A (GLA) gene that result in deficient galactosidase A enzyme and subsequent accumulation of glycosphingolipids throughout the body. The result is a multi-system disorder characterized by cutaneous, corneal, cardiac, renal, and neurological manifestations. Increased left ventricular wall thickness represents the predominant cardiac manifestation of FD. As the disease progresses, patients may develop arrhythmias, advanced conduction abnormalities, and heart failure. Cardiac biomarkers, point-of-care dried blood spot testing, and advanced imaging modalities including echocardiography with strain imaging and magnetic resonance imaging (MRI) with T1 mapping now allow us to detect Fabry cardiomyopathy much more effectively than in the past. While enzyme replacement therapy (ERT) has been the mainstay of treatment, several promising therapies are now in development, making early diagnosis of FD even more crucial. Ongoing initiatives involving artificial intelligence (AI)-empowered interpretation of echocardiographic images, point-of-care dried blood spot testing in the echocardiography laboratory, and widespread dissemination of point-of-care ultrasound devices to community practices to promote screening may lead to more timely diagnosis of FD. Fabry disease should no longer be considered a rare, untreatable disease, but one that can be effectively identified and treated at an early stage before the development of irreversible end-organ damage.<\/jats:p>","DOI":"10.3390\/cells10061532","type":"journal-article","created":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T11:20:26Z","timestamp":1623928826000},"page":"1532","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Fabry Cardiomyopathy: Current Practice and Future Directions"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9792-6533","authenticated-orcid":false,"given":"Jeffrey","family":"Yim","sequence":"first","affiliation":[{"name":"Department of Medicine, University of British Columbia, Vancouver, BC V6H 0A5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Yau","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of British Columbia, Vancouver, BC V6H 0A5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darwin F.","family":"Yeung","sequence":"additional","affiliation":[{"name":"Vancouver General Hospital and University of British Columbia Echocardiography Laboratory, Division of Cardiology, University of British Columbia, Vancouver, BC V6H 0A5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa S. M.","family":"Tsang","sequence":"additional","affiliation":[{"name":"Vancouver General Hospital and University of British Columbia Echocardiography Laboratory, Division of Cardiology, University of British Columbia, Vancouver, BC V6H 0A5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/humu.21074","article-title":"Newborn screening for fabry disease in taiwan reveals a high incidence of the later-onset GLA mutation c.936 + 919G > A (IVS4 + 919G > A)","volume":"30","author":"Hwu","year":"2009","journal-title":"Hum. Mutat."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.echo.2018.01.016","article-title":"Echocardiographic Assessment of Patients with Fabry Disease","volume":"31","author":"Yeung","year":"2018","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jacc.2020.12.024","article-title":"Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week","volume":"77","author":"Pieroni","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.beem.2014.10.003","article-title":"Fabry disease and the heart","volume":"29","author":"Seydelmann","year":"2015","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0009-8981(01)00478-8","article-title":"Fabry disease: Enzymatic diagnosis in dried blood spots on filter paper","volume":"308","author":"Chamoles","year":"2001","journal-title":"Clin. Chim. Acta"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmg.2008.065904","article-title":"Natural course of Fabry disease: Changing pattern of causes of death in FOS-Fabry Outcome Survey","volume":"46","author":"Mehta","year":"2009","journal-title":"J. Med. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/ejhf.1960","article-title":"An expert consensus document on the management of cardiovascular manifestations of Fabry disease","volume":"22","author":"Linhart","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An Atypical Variant of Fabry\u2019s Disease in Men with Left Ventricular Hypertrophy","volume":"333","author":"Nakao","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.jacc.2016.09.943","article-title":"Later Onset Fabry Disease, Cardiac Damage Progress in Silence: Experience With a Highly Prevalent Mutation","volume":"68","author":"Hsu","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.amjcard.2005.05.033","article-title":"Prevalence and clinical significance of cardiac arrhythmia in Anderson-Dabry disease","volume":"96","author":"Shah","year":"2005","journal-title":"Am. J. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-8-116","article-title":"Fibrosis: A key feature of Fabry disease with potential therapeutic implications","volume":"8","author":"Weidemann","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1093\/europace\/eur267","article-title":"Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease","volume":"13","author":"Omahony","year":"2011","journal-title":"Europace"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fcvm.2016.00007","article-title":"Electrocardiographic Changes and Arrhythmia in Fabry Disease","volume":"3","author":"Namdar","year":"2016","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1136\/hrt.2010.204586","article-title":"The right ventricle in Fabry disease: Natural history and impact of enzyme replacement therapy","volume":"96","author":"Niemann","year":"2010","journal-title":"Heart"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2008.03.007","article-title":"Onset and progression of the Anderson-Fabry disease related cardiomyopathy","volume":"130","author":"Kampmann","year":"2008","journal-title":"Int. J. Cardiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0002-8703(77)80064-1","article-title":"Electrocardiographic and vectorcardiographic abnormalities in Fabry\u2019s disease","volume":"93","author":"Mehta","year":"1977","journal-title":"Am. Heart J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1067\/mhj.2000.105105","article-title":"New insights in cardiac structural changes in patients with Fabry\u2019s disease","volume":"139","author":"Linhart","year":"2000","journal-title":"Am. Heart J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/eurheartj\/ehp426","article-title":"Aortic remodelling in Fabry disease","volume":"31","author":"Barbey","year":"2010","journal-title":"Eur. Heart J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1161\/01.CIR.54.5.818","article-title":"Cardiac valvular anomalies in Fabry disease. Clinical, morphologic, and biochemical studies","volume":"54","author":"Desnick","year":"1976","journal-title":"Circulation"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.CIR.0000012626.81324.38","article-title":"Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy","volume":"105","author":"Sachdev","year":"2002","journal-title":"Circulation"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"200.e1","DOI":"10.1016\/j.amjmed.2017.09.010","article-title":"Identification of Fabry Disease in a Tertiary Referral Cohort of Patients with Hypertrophic Cardiomyopathy","volume":"131","author":"Maron","year":"2018","journal-title":"Am. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1136\/jmedgenet-2017-105080","article-title":"Fabry Disease: Prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995\u20132017","volume":"55","author":"Doheny","year":"2018","journal-title":"J. Med. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCGENETICS.109.862920","article-title":"High incidence of the cardiac variant of fabry disease revealed by newborn screening in the Taiwan Chinese population","volume":"2","author":"Lin","year":"2009","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"f153","DOI":"10.1093\/europace\/eux261","article-title":"Ventricular arrhythmia and sudden cardiac death in Fabry disease: A systematic review of risk factors in clinical practice","volume":"20","author":"Baig","year":"2018","journal-title":"Europace"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin. Genet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"J. Am. Med. Assoc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/ejechocard\/jer112","article-title":"The endocardial binary appearance (\u2018binary sign\u2019) is an unreliable marker for echocardiographic detection of Fabry disease in patients with left ventricular hypertrophy","volume":"12","author":"Mundigler","year":"2011","journal-title":"Eur. J. Echocardiogr."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1540-8175.2012.01704.x","article-title":"Systolic myocardial mechanics in patients with Anderson-Fabry disease with and without left ventricular hypertrophy and in comparison to nonobstructive hypertrophic cardiomyopathy","volume":"29","author":"Gruner","year":"2012","journal-title":"Echocardiography"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/echo.13496","article-title":"Loss of base-to-apex circumferential strain gradient: A specific pattern of Fabry cardiomyopathy?","volume":"34","author":"Labombarda","year":"2017","journal-title":"Echocardiography"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Hindieh, W., Weissler-Snir, A., Hammer, H., Adler, A., Rakowski, H., and Chan, R.H. (2017). Discrepant Measurements of Maximal Left Ventricular Wall Thickness Between Cardiac Magnetic Resonance Imaging and Echocardiography in Patients With Hypertrophic Cardiomyopathy. Circ. Cardiovasc. Imaging, 10.","DOI":"10.1161\/CIRCIMAGING.117.006309"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"108","DOI":"10.21037\/atm-20-4891","article-title":"Artificial intelligence-based myocardial texture analysis in etiological differentiation of left ventricular hypertrophy","volume":"9","author":"Yu","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Goto, S., Mahara, K., Beussink-Nelson, L., Ikura, H., Katsumata, Y., Endo, J., Gaggin, H.K., Shah, S.J., Itabashi, Y., and MacRae, C.A. (2021). Artificial intelligence-enabled fully automated detection of cardiac amyloidosis using electrocardiograms and echocardiograms. Nat. Commun., 12.","DOI":"10.1038\/s41467-021-22877-8"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/S2589-7500(20)30267-3","article-title":"Diagnosis and risk stratification in hypertrophic cardiomyopathy using machine learning wall thickness measurement: A comparison with human test-retest performance","volume":"3","author":"Augusto","year":"2021","journal-title":"Lancet Digit. Health"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1161\/CIRCULATIONAHA.119.039291","article-title":"Response by Zhang and Deo to Letter Regarding Article, \u201cFully Automated Echocardiogram Interpretation in Clinical Practice: Feasibility and Diagnostic Accuracy\u201d","volume":"139","author":"Zhang","year":"2019","journal-title":"Circulation"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/CIRCIMAGING.112.000070","article-title":"Identification and assessment of anderson-fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping","volume":"6","author":"Sado","year":"2013","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12968-014-0099-4","article-title":"Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance","volume":"16","author":"Pica","year":"2014","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"10171","DOI":"10.1161\/CIRCIMAGING.119.010171","article-title":"Myocardial edema, myocyte injury, and disease severity in Fabry disease","volume":"13","author":"Augusto","year":"2020","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Seydelmann, N., Liu, D., Kr\u00e4mer, J., Drechsler, C., Hu, K., Nordbeck, P., Schneider, A., St\u00f6rk, S., Bijnens, B., and Ertl, G. (2016). High-sensitivity troponin: A clinical blood biomarker for staging cardiomyopathy in fabry disease. J. Am. Heart Assoc., 5.","DOI":"10.1161\/JAHA.115.002839"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Yogasundaram, H., Nikhanj, A., Putko, B.N., Boutin, M., Jain-Ghai, S., Khan, A., Auray-Blais, C., West, M.L., and Oudit, G.Y. (2018). Elevated inflammatory plasma biomarkers in patients with fabry disease: A critical link to heart failure with preserved ejection fraction. J. Am. Heart Assoc., 7.","DOI":"10.1161\/JAHA.118.009098"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10545-007-0716-6","article-title":"Correlation between interleukin-6 promoter and C-reactive protein (CRP) polymorphisms and CRP levels with the Mainz Severity Score Index for Fabry disease","volume":"31","author":"Altarescu","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.amjcard.2012.08.055","article-title":"Role of serum N-terminal pro-brain natriuretic peptide measurement in diagnosis of cardiac involvement in patients with anderson-fabry disease","volume":"111","author":"Coats","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1445-5994.2008.01669.x","article-title":"Cardiovascular testing in Fabry disease: Exercise capacity reduction, chronotropic incompetence and improved anaerobic threshold after enzyme replacement","volume":"38","author":"Lobo","year":"2008","journal-title":"Intern. Med. J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1159\/000087675","article-title":"Cardiopulmonary exercise testing in fabry disease","volume":"72","author":"Bierer","year":"2005","journal-title":"Respiration"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1002\/ajmg.a.40369","article-title":"Cardiopulmonary fitness assessment on maximal and submaximal exercise testing in patients with Fabry disease","volume":"176","author":"Powell","year":"2018","journal-title":"Am. J. Med. Genet. Part A"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s10545-006-0361-5","article-title":"Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease","volume":"29","author":"Bierer","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ymgme.2009.10.178","article-title":"A validated disease severity scoring system for Fabry disease","volume":"99","author":"Giannini","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1399-0004.2004.00219.x","article-title":"The Mainz Severity Score Index: A new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy","volume":"65","author":"Whybra","year":"2004","journal-title":"Clin. Genet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/ckj\/sfw082","article-title":"FAbry STabilization indEX (FASTEX): An innovative tool for the assessment of clinical stabilization in Fabry disease","volume":"9","author":"Mignani","year":"2016","journal-title":"Clin. Kidney J."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Khan, A., Barber, D.L., Huang, J., Rupar, C.A., Rip, J.W., Auray-Blais, C., Boutin, M., O\u2019Hoski, P., Gargulak, K., and McKillop, W.M. (2021). Lentivirus-mediated gene therapy for Fabry disease. Nat. Commun., 12.","DOI":"10.1038\/s41467-021-21371-5"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and Efficacy of Recombinant Human \u03b1-Galactosidase A Replacement Therapy in Fabry\u2019s Disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on fabry cardiomyopathy. Evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","article-title":"Improvement of cardiac function during enzyme replacement therapy in patients with fabry disease: A prospective strain rate imaging study","volume":"108","author":"Weidemann","year":"2003","journal-title":"Circulation"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/jimd.12228","article-title":"Developments in the treatment of Fabry disease","volume":"43","author":"Hollak","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_56","first-page":"2743","article-title":"Enzyme Replacement Therapy in Fabry Disease: A Randomized Controlled Trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"El Dib, R., Gomaa, H., Carvalho, R.P., Camargo, S.E., Bazan, R., Barretti, P., and Barreto, F.C. (2016). Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD006663.pub4"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ymgme.2014.01.014","article-title":"Outcomes of patients treated through the Canadian Fabry disease initiative","volume":"111","author":"Sirrs","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/jmedgenet-2017-104863","article-title":"Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: An international cohort study","volume":"55","author":"Arends","year":"2018","journal-title":"J. Med. Genet."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s Disease with the Pharmacologic Chaperone Migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_61","first-page":"S111","article-title":"Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: In vitro and preclinical studies","volume":"47","author":"Germain","year":"2009","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J. Med. Genet."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/s41436-019-0451-z","article-title":"Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: Data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study","volume":"21","author":"Germain","year":"2019","journal-title":"Genet. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2119\/molmed.2015.00088","article-title":"Efficacy of enzyme and substrate reduction therapy with a novel antagonist of glucosylceramide synthase for fabry disease","volume":"21","author":"Ashe","year":"2015","journal-title":"Mol. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"20019","DOI":"10.1038\/srep20019","article-title":"Intrathecal delivery of frataxin mRNA encapsulated in lipid nanoparticles to dorsal root ganglia as a potential therapeutic for Friedreich\u2019s ataxia","volume":"6","author":"Nabhan","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1017\/S1047951120003145","article-title":"Feasibility and diagnostic performance of including point-of-care ultrasound (POCUS) in preparticipation screening of young competitive athletes","volume":"30","year":"2020","journal-title":"Cardiol. Young"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.7863\/ultra.16.06044","article-title":"Hypertrophic Cardiomyopathy in Youth Athletes: Successful Screening with Point-of-Care Ultrasound by Medical Students: Successful","volume":"36","author":"Fox","year":"2017","journal-title":"J. Ultrasound Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cjca.2018.11.003","article-title":"Feasibility and Reliability of Nonexpert POCUS for Cardiovascular Preparticipation Screening of Varsity Athletes: The SHARP Protocol","volume":"35","author":"Moulson","year":"2019","journal-title":"Can. J. Cardiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jacc.2019.12.030","article-title":"Detection of Hypertrophic Cardiomyopathy Using a Convolutional Neural Network-Enabled Electrocardiogram","volume":"75","author":"Ko","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Martini, N., Aimo, A., Barison, A., Della Latta, D., Vergaro, G., Aquaro, G.D., Ripoli, A., Emdin, M., and Chiappino, D. (2020). Deep learning to diagnose cardiac amyloidosis from cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson., 22.","DOI":"10.1186\/s12968-020-00690-4"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/6\/1532\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:17:51Z","timestamp":1760163471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/6\/1532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,17]]},"references-count":70,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["cells10061532"],"URL":"https:\/\/doi.org\/10.3390\/cells10061532","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,17]]}}}